VJHemOnc is committed to improving our service to you

ASH 2019 | Pivotal safety and efficacy results for liso-cel in R/R B-NHL

VJHemOnc is committed to improving our service to you

Jeremy Abramson

Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, discusses the pivotal safety and efficacy results from the TRANSCEND-NHL-001 study (NCT02631044). This is a phase I study evaluating lisocabtagene maraleucel (liso-cel), an investigational, anti-CD19 CAR T-cell product, in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Abramson highlights the very encouraging results, including durable clinical activity and a favorable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter